NY-THE-VALENCE-GROUP
The Valence Group advised Solenis on its combination with BASF of their paper and water chemical businesses. The combined company will have pro-forma sales of around $3 billion and intends to operate under the Solenis brand. The new combination is positioned to provide expanded chemical offerings and cost-effective solutions for customers in pulp, paper, oil and gas, chemical processing, mining, biorefining, power, municipal and other industrial markets.
BASF will own 49 percent of the combined company and 51 percent is collectively owned by Solenis management and funds managed by Clayton, Dubilier & Rice (CD&R). The new Solenis has approximately 5,200 employees, with increased sales, service and production capabilities across the globe.
The merger includes the Paper and Water assets of BASF’s Performance Chemicals unit, including production sites in Bradford and Grimsby, UK; Suffolk, Virginia, USA; Altamira, Mexico; Ankleshwar, India; and Kwinana, Australia and related assets including intellectual property. BASF’s paper coating chemical business is not part of the transaction.
About Solenis
Solenis is a leading global producer of specialty chemicals for water intensive industries, including the pulp, paper, oil and gas, chemical processing, mining, biorefining, power and municipal markets. The company’s product portfolio includes a broad array of process, functional and water treatment chemistries as well as state-of-the-art monitoring and control systems. These technologies are used by customers to improve operational efficiencies, enhance product quality, protect plant assets and minimize environmental impact. Headquartered in Wilmington, Delaware, the company has 35 manufacturing facilities strategically located around the globe in 118 countries across five continents.
About BASF
With more than 115,000 employees in the BASF Group, the portfolio is organized into five segments: Chemicals, Performance Products, Functional Materials & Solutions, Agricultural Solutions and Oil & Gas. BASF generated sales of €64.5 billion in 2017. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (BAS).
About The Valence Group
The Valence Group is a specialist investment bank offering M&A advisory services exclusively to companies and investors in the chemicals, materials and related sectors. The Valence Group team includes a unique combination of professionals with backgrounds in investment banking and strategy consulting within the chemicals and materials industries, all focused exclusively on providing M&A advisory services to the chemicals and materials sector. The firm’s offices are located in New York and London.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190206005585/en/
Contact:
The Valence Group Paul Lakind, 212-847-7339 plakind@valencegroup.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting styrker kapaciteten med samarbejdsfirmaet Market One30.6.2025 01:12:00 CEST | Pressemeddelelse
Andersen Consulting fortsætter udvidelsen af sin globale platform gennem en samarbejdsaftale med Market One, et konsulentfirma med base i Argentina, der specialiserer sig i kommercielle end-to-end-løsninger. Market One har hovedkontor i Argentina og er et førende konsulentfirma med speciale i kommerciel transformation i alle processens faser. Firmaet blev stiftet i 2009 af partnerne Esteban Neville og Jerónimo Fernández Abeijón og har en praktisk, resultatorienteret tilgang til alle projekter – de følger kunderne fra strategi til udførelse. Ekspertisen spænder over strategisk rådgivning, kommerciel optimering, teknologiaktivering og indsigtsdrevet beslutningstagning. Med en dokumenteret erfaring fra over 1.200 projekter i mere end 20 lande arbejder Market One med nogle af de mest anerkendte brands i verden og hjælper dem med at styrke deres kommercielle kapacitet og opnå bæredygtig vækst. "Vi er født til at løse problemer, men det er måden, vi gør det på, der adskiller os fra andre," s
SBC Medical added to membership of Russell 3000® Index28.6.2025 01:30:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/ Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000®Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to
Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse27.6.2025 22:44:00 CEST | Press release
Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive agreement to acquire SLK Software (“SLK”), a global technology services firm focused on delivering AI, intelligence automation and analytics solutions. The acquisition will further strengthen Altimetrik’s end-to-end enablement services and expand its customer reach, with a clear path to accelerate towards Altimetrik’s goal of reaching $1billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of 2025. Financial details were not disclosed. Founded in 2000, SLK is recognized as a leader in the tech industry, and for its commitment to create innovative digital solutions. This strategic acquisition will significantly enhance the scale of Altimetrik’s capabilities, bringing together Altimetrik’s AI-first, platform-native engineering model and SLK’s full technology services stack that will further
Andersen Consulting udvider sine kompetencer inden for forretningstransformation med tilføjelsen af The Clearing27.6.2025 16:48:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin platform med samarbejdsfirmaet The Clearing, som er en managementkonsulentvirksomhed med speciale i organisatorisk omstilling og lederudvikling. The Clearing blev stiftet i 2009 og rådgiver kunder om komplekse udfordringer ved at afstemme ledelse, strategi, kultur og drift. Firmaet arbejder med føderale agenturer, virksomheder og nonprofitorganisationer med henblik på at skabe målbare forandringer på tværs af forskellige interessenter til gavn for en leders vision og strategi. Med dyb erfaring inden for flere sektorer, herunder national sikkerhed, sundhedspleje og finansielle tjenester, leder The Clearings unikke blanding af talent med ekspertise inden for organisationsudvikling, dataanalyse og visuel rådgivning forretningstransformationer i stor skala og arbejder sammen med kunder og eksperter for at sikre, at rådgivning omsættes til implementering. "Vi leverer transformative resultater, der ikke kun er i overensstemmelse med strategiske mål, men også
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD00127.6.2025 16:00:00 CEST | Press release
PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. “We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in hu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom